- Home
- TEAF vs YMAB Comparison
TEAF vs YMAB Comparison
Compare TEAF & YMAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TEAF
- YMAB
- Stock Information
- Founded
- TEAF 2017
- YMAB 2015
- Country
- TEAF United States
- YMAB United States
- Employees
- TEAF N/A
- YMAB N/A
- Industry
- TEAF Trusts Except Educational Religious and Charitable
- YMAB Biotechnology: Pharmaceutical Preparations
- Sector
- TEAF Finance
- YMAB Health Care
- Exchange
- TEAF Nasdaq
- YMAB Nasdaq
- Market Cap
- TEAF 163.0M
- YMAB 192.4M
- IPO Year
- TEAF N/A
- YMAB 2018
- Fundamental
- Price
- TEAF $12.21
- YMAB $4.30
- Analyst Decision
- TEAF
- YMAB Buy
- Analyst Count
- TEAF 0
- YMAB 10
- Target Price
- TEAF N/A
- YMAB $17.00
- AVG Volume (30 Days)
- TEAF 56.1K
- YMAB 185.8K
- Earning Date
- TEAF 01-01-0001
- YMAB 08-11-2025
- Dividend Yield
- TEAF 9.20%
- YMAB N/A
- EPS Growth
- TEAF N/A
- YMAB N/A
- EPS
- TEAF N/A
- YMAB N/A
- Revenue
- TEAF N/A
- YMAB $88,658,000.00
- Revenue This Year
- TEAF N/A
- YMAB N/A
- Revenue Next Year
- TEAF N/A
- YMAB $15.15
- P/E Ratio
- TEAF N/A
- YMAB N/A
- Revenue Growth
- TEAF N/A
- YMAB 4.92
- 52 Week Low
- TEAF $11.11
- YMAB $3.55
- 52 Week High
- TEAF $13.30
- YMAB $16.11
- Technical
- Relative Strength Index (RSI)
- TEAF 58.26
- YMAB 45.90
- Support Level
- TEAF $12.13
- YMAB $4.20
- Resistance Level
- TEAF $12.23
- YMAB $4.42
- Average True Range (ATR)
- TEAF 0.10
- YMAB 0.22
- MACD
- TEAF -0.02
- YMAB -0.01
- Stochastic Oscillator
- TEAF 46.44
- YMAB 38.10
About TEAF Ecofin Sustainable and Social Impact Term Fund
Tortoise Essential Assets Income Term is a USA-based non-diversified, closed-end management investment company. Its investment objective is to provide common shareholders with a high level of total return with an emphasis on current distributions.
About YMAB Y-mAbs Therapeutics Inc.
Y-mAbs Therapeutics Inc is a commercial-stage biopharmaceutical company. It is mainly engaged in the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer. DANYELZA, is the first FDA-approved product of the company which is a recombinant humanized immunoglobulin G, subtype 1k, or IgG1k, monoclonal antibody or mAb that targets ganglioside GD2, which is expressed in various neuroectoderm-derived tumors and sarcomas.